Gland Pharma has appointed Deepak Sapra, a senior executive at Dr Reddy’s Laboratories, as its new Chief Executive Officer, marking a significant leadership change at the Hyderabad-based pharmaceutical company. Sapra will take charge as CEO on November 16, 2026, subject to his acceptance of the offer, the company said in a stock exchange filing.
The appointment comes at an important stage for Gland Pharma, which is looking to build on improving financial performance while expanding its presence in complex injectables, contract development and manufacturing services, or CDMO, and international markets. The company’s board approved Sapra’s appointment following the recommendation of its Nomination and Remuneration Committee.
Sapra brings nearly three decades of pharmaceutical industry experience to the role. Digital Health News reported that he has 27 years of executive experience, including more than 23 years in the pharmaceutical sector. His career has covered active pharmaceutical ingredients, generic medicines, CDMO operations, business development, licensing, portfolio management and international expansion.
At Dr Reddy’s, Sapra currently serves as Chief Executive Officer of the API and Services business. He has been responsible for an integrated portfolio covering APIs, generic pharmaceuticals, CDMO services and strategic collaborations. His experience spans major pharmaceutical markets including the US, Europe, Japan, Latin America, Africa and the Asia-Pacific region.
One of the most relevant parts of Sapra’s background for Gland Pharma is his experience in contract manufacturing. Earlier in his career, he headed Dr Reddy’s Custom Pharmaceutical Services business, where he led global CDMO operations serving innovator pharmaceutical companies in the US, Europe and Japan. He has also handled global generics business development and portfolio management.
That experience could be particularly useful as Gland Pharma seeks to expand its CDMO business. Earlier this month, the company announced a strategic manufacturing and supply agreement with a global pharmaceutical company covering technology transfer, production and supply of sterile injectable products for worldwide markets. Gland Pharma expects the agreement to generate annual revenue of about $90 million to $100 million once fully operational.
The appointment also follows a period of strong financial performance for Gland Pharma. The company reported a 47% year-on-year increase in consolidated profit in the first quarter of FY27, while revenue rose 20%. Its strong results had already lifted investor interest in the stock, with Gland Pharma shares gaining more than 12% after the earnings announcement.
Gland Pharma’s official investor data also shows that the company has reported Q1 FY27 results and earnings-related disclosures as part of its current financial year. The stronger quarterly performance gives Sapra a relatively favourable starting point, although maintaining that momentum will be one of his immediate challenges.
The company operates primarily in the pharmaceutical manufacturing space, with a strong focus on injectable products. Its business includes the development, manufacture, sale and distribution of pharmaceuticals. Gland Pharma has also built an international footprint through subsidiaries and operations serving markets outside India.
Sapra’s appointment is also notable because Gland Pharma has gone through leadership changes in recent years. Shyamakant Giri had joined the company as CEO in January 2025, after Srinivas Sadu was redesignated as Executive Chairman. Gland Pharma’s corporate disclosures subsequently recorded Giri’s resignation as CEO in March 2026.
The company’s leadership structure currently includes Executive Chairman Srinivas Sadu, along with an experienced board that includes independent directors such as Naina Lal Kidwai and William Robert Keller.
For Sapra, the new role will involve balancing Gland Pharma’s established injectable business with opportunities in higher-value pharmaceutical manufacturing. The global CDMO market, complex injectables and specialised pharmaceutical products offer opportunities for Indian manufacturers with regulatory capabilities and established international customer relationships.
His background in APIs and services could also help Gland Pharma strengthen the connection between product development, manufacturing and global commercial opportunities. His experience in mergers and acquisitions, licensing and portfolio strategy may further support the company as it evaluates new partnerships and expansion opportunities.
The focus for investors is likely to remain on whether the leadership change translates into sustained revenue growth, stronger margins and greater visibility for Gland Pharma’s international business. The company has already demonstrated improving earnings, while its recent CDMO agreement points to an effort to secure larger and more integrated global contracts.
Sapra will therefore take over at a time when the company has both momentum and clear opportunities ahead. His experience at Dr Reddy’s gives him familiarity with global pharmaceutical markets, regulatory requirements and complex manufacturing operations. The challenge will be to convert that experience into faster growth while maintaining operational discipline and quality standards.
With his appointment scheduled for November 16, the transition will take place over the coming months. Until then, investors and the pharmaceutical industry will be watching how Gland Pharma prepares for the change and whether Sapra’s arrival signals a broader push into high-value injectables, CDMO services and global expansion.